70686049
liked
$MicroCloud Hologram(HOLO.US$ coming to its hsitrocial low of 1.5 👀
3
2
70686049
liked
📣 3 PDUFAs left in April! See summary 👇
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
11
4
70686049
reacted to
$X4 Pharmaceuticals(XFOR.US$
NEWS
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
XOLREMDI™ has been approved by the FDA, marking a significant achievement for X4 Pharmaceuticals. The drug is the first indication for the treatment of WHIM syndrome and has shown positive results in the clinical trial, with improvements in ANC, ALC, and fewer infections. X4 has also received a Rare Pediatric Disease Priority Review...
NEWS
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
XOLREMDI™ has been approved by the FDA, marking a significant achievement for X4 Pharmaceuticals. The drug is the first indication for the treatment of WHIM syndrome and has shown positive results in the clinical trial, with improvements in ANC, ALC, and fewer infections. X4 has also received a Rare Pediatric Disease Priority Review...
2
70686049
reacted to
$X4 Pharmaceuticals(XFOR.US$ X4 Pharmaceuticals Announces FDA Approval of Xolremdi™ (Mavorixafor) Capsules, First Drug Indicated in Patients With Whim Syndrome
2
70686049
reacted to
$X4 Pharmaceuticals(XFOR.US$ FDA Approves X4 Pharmaceuticals' Xolremdi (Mavorixafor) Capsules For Use In Patients 12 Years Of Age And Older With WHIM Syndrome To Increase The Number Of Circulating Mature Neutrophils And Lymphocytes
5
4
70686049
reacted to
$Aquestive Therapeutics(AQST.US$
EARNINGS PREVIEW
Aquestive Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Aquestive Therapeutics Inc AQST.OQ AQST.O is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2024
The Warren New Jersey-based company is expected to report a 10.1% increase in revenue to $12.262 million from $11.13 million a year ago, according to the mean estimate from 8 analysts, based on LSEG da...
EARNINGS PREVIEW
Aquestive Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Aquestive Therapeutics Inc AQST.OQ AQST.O is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2024
The Warren New Jersey-based company is expected to report a 10.1% increase in revenue to $12.262 million from $11.13 million a year ago, according to the mean estimate from 8 analysts, based on LSEG da...
4
70686049
liked
$Aquestive Therapeutics(AQST.US$ Bigger dip so I can buy more
1